Promising Developments and Market Potential Drive Buy Rating for Viridian Therapeutics
I'm PortAI, I can summarize articles.
TD Cowen analyst Joseph Thome maintains a Buy rating for Viridian Therapeutics, citing promising developments like veligrotug's potential approval for thyroid eye disease and positive Phase III trial results for VRDN-003. These advancements, along with favorable administration profiles, suggest strong market potential. Despite regulatory risks, the pipeline supports the Buy rating. Thome, a 5-star analyst, has an average return of 11.4% and a 54.14% success rate. H.C. Wainwright also maintains a Buy rating with a $34.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments